Fallopian Tube Lesions: What These Precancerous Findings Mean for Your Health

Fallopian tube lesions are emerging as critical pieces in the ovarian cancer puzzle, and they’re changing how doctors think about prevention and early detection. 

If you’ve recently had surgery and received news about abnormal findings in your fallopian tubes, you’re not alone. Doctors are finding these precancerous changes with increasing frequency — and the main reason isn’t that they’re becoming more common. It’s that pathologists are looking more carefully. 

Comprehensive pathological examinations of the fallopian tubes are now routinely conducted in clinical practice, leading to the incidental discovery of STICs and STILs with increasing frequency. 

Much of this shift traces back to the adoption of the SEE-FIM protocol and a deeper understanding of the fallopian tube’s role in ovarian cancer: tools and knowledge that simply didn’t exist a generation ago. What you do with this information matters.

• What are Fallopian Tube Lesions?
• The Fallopian Tube – Ovarian Cancer Connection
• The Three Types of Fallopian Tube Lesions
• How Are These Lesions Discovered?
• Who’s at Risk for Developing Fallopian Tube Lesions?
• What Happens If You’re Diagnosed with a Fallopian Tube Lesion?
• Prevention Strategies

What Are Fallopian Tube Lesions?

Your fallopian tubes aren’t just passive corridors for eggs traveling from your ovaries to your uterus. Research now shows they’re actually ground zero for many cases of what we’ve traditionally called “ovarian cancer.”

Fallopian tube lesions represent a spectrum of cellular changes that can occur in the epithelium (the tissue lining) of your fallopian tubes. These changes range from very early abnormalities to more advanced precancerous conditions. 

The three main types you might hear about are:

• P53 signatures: The earliest detectable change, involving about 12 or more consecutive secretory cell nuclei with abnormal p53 staining. P53 is a protein that normally helps prevent cancer by controlling cell growth and repairing DNA damage. When the gene that makes this protein mutates, the protein builds up in cells instead of working properly. Under the microscope, these cells still look mostly normal — but they’re already under stress. Think of them as a ticking time bomb: outwardly unremarkable, but carrying a molecular fault that can set everything in motion.
• Serous Tubal Intraepithelial Lesions (STIL): An intermediate stage sitting between p53 signatures and STIC. These cells show abnormal p53 immunostaining (like p53 signatures) but don’t yet have the full features of malignancy seen in STIC. There’s no specific cell count that defines them; what matters is how they look and behave under the microscope. They’re dividing faster than normal, starting to look different from healthy tissue, and showing clear signs of cellular distress. But they haven’t crossed the line into carcinoma yet.
• Serous Tubal Intraepithelial Carcinoma (STIC): The most advanced precancerous lesion, showing significant cellular changes and higher proliferation rates. These cells have lost their normal structure and are multiplying rapidly, though they haven’t yet invaded surrounding tissue.

The Fallopian Tube Connection: Rewriting Ovarian Cancer’s Origin Story

For decades, doctors believed ovarian cancer started in the ovaries themselves. But groundbreaking research has turned that assumption upside down.

Studies show that up to 60 to 70% of high-grade serous ovarian cancers (the most common type) actually originate in the fallopian tubes, specifically at the fimbriated end where the tube meets the ovary. 

Here’s what appears to happen: abnormal cells develop in the fallopian tube, particularly at the tubal-peritoneal junction. Over time, these cells can shed from the tube and implant on the ovary or throughout the pelvic cavity. What looks like ovarian cancer is often fallopian tube cancer that has spread.

This discovery matters enormously for the prevention and early detection of ovarian cancer. And it’s especially relevant if you’re considering surgery for benign reasons or if you carry genetic mutations that increase cancer risk.

Understanding the Three Types of Fallopian Tube Lesions

Each type of fallopian tube lesion represents a different level of cellular change. Knowing where you fall on this spectrum helps determine what comes next.

P53 Signatures: The Earliest Warning Sign

P53 signatures are the most subtle finding: often just a small cluster of cells (around 10 to 20) that show abnormal accumulation of the p53 protein. The p53 gene acts as your body’s “guardian of the genome,” helping prevent cancer by controlling cell division and triggering damaged cells to self-destruct.

When this gene mutates, the protein it produces accumulates in cells instead of functioning properly. P53 signatures can be detected in normal-appearing fallopian tube tissue, and research suggests they may persist for years or even decades before progressing to more advanced lesions. 

Importantly, p53 signatures have been found in up to 25% of women with BRCA mutations who undergo risk-reducing surgery, but they’re also present in women without known genetic risks.

STIL: The Middle Ground

Serous Tubal Intraepithelial Lesions represent a step up in concern. With STIL, you have:

• Abnormal p53 immunostaining that doesn’t yet meet the threshold for STIC
• Some morphological (structural) abnormalities
• A higher Ki-67 proliferative index (10 to 40%), meaning cells are dividing more rapidly than normal

Some researchers have described STIL as potentially “dormant” lesions that could take more than a decade to progress — if they progress at all. The metabolic profile of STIL shows decreased energy production pathways, which might explain why these lesions can remain stable for extended periods.

STIC: The Most Advanced Precursor

Serous Tubal Intraepithelial Carcinoma is the most concerning finding. STIC lesions show:

• High levels of p53 protein mutation accumulation
• Significant architectural and nuclear abnormalities
• High proliferative activity
• Loss of normal cell polarity and structure

Research has found that when STIC is identified in women with high-grade serous carcinoma, the exact same TP53 mutation is present in both the STIC and the ovarian tumor, confirming they’re the same disease. 

Between 50 to 75% of advanced pelvic serous carcinomas show evidence of STIC when fallopian tubes are carefully examined. And here’s the critical timeline: research suggests STIC can progress to invasive high-grade serous carcinoma within 5 to 7 years.

How Are These Lesions Discovered?

Most fallopian tube lesions are found incidentally: meaning, they’re discovered during surgery performed for other reasons. You might have had a hysterectomy for fibroids, an oophorectomy surgery for benign cysts, or risk-reducing surgery due to BRCA mutations.

The key to finding these lesions lies in how your surgical specimen is examined. Standard pathology protocols might miss them entirely.

The SEE-FIM Protocol: A Game-Changer

The SEE-FIM protocol (Sectioning and Extensively Examining the FIMbriated end) involves taking very thin sections of the fallopian tube and examining them microscopically. This detailed approach has dramatically increased detection of STIC and other precancerous changes that would have been missed with standard examination.

The challenge? Adoption isn’t universal. 

While NCCN and ACOG recommend the SEE-FIM protocol for risk-reducing surgeries, there’s a significant gap in practice: 91% of gynecologic oncologists follow it, but only 41% of benign OB-GYNs do. 

That disparity matters, because many risk-reducing surgeries — including those performed on BRCA-positive patients — happen outside of oncology settings, where the protocol is far less likely to be used. The result: some lesions go undetected entirely.

Who’s at Risk for Developing Fallopian Tube Lesions?

Genetic factors. Women with BRCA1 or BRCA2 mutations face significantly elevated risk. While the general population has about a 1.2 to 1.4% lifetime risk of developing ovarian cancer, BRCA mutation carriers can have risks up to 46%.

Research shows that in BRCA-positive women undergoing risk-reducing surgery, more than 50% who had STIC showed evidence of multiple tubal precursor lesions, suggesting a higher burden of abnormal changes increases cancer risk.

But genetic mutations aren’t the whole story. Fallopian tube lesions can develop in women without any known hereditary predisposition.

Other risk factors. Age matters. The likelihood of detecting STIC increases with advancing age, particularly in women over 50. This aligns with the observation that most ovarian cancer diagnoses occur in women 63 years or older.

Repeated ovulation also appears to play a role. The mechanical trauma and exposure to reactive oxygen species released during ovulation may damage fallopian tube epithelium over time, potentially triggering malignant transformation.

What Happens If You’re Diagnosed with a Fallopian Tube Lesion?

Finding out you have a precancerous change in your fallopian tubes can be frightening. But having this information gives you options.

For P53 Signatures and STIL

If you’re diagnosed with p53 signatures or STIL found incidentally, it’s important to know that these findings are primarily of research interest and don’t necessarily change your day-to-day medical management. These early-stage changes don’t always progress, and the timeline to cancer — if it happens at all — can span decades.

In most cases, you don’t need to be seen routinely by a gynecologic oncologist. Your regular OB-GYN can monitor you. There’s no clear consensus recommending routine ultrasounds or CA-125 ovarian cancer screening for these findings specifically, though your physician may still suggest them based on your individual situation.

The most meaningful conversation to have with your doctor is about your longer-term options: particularly, if you’ve completed childbearing, whether a bilateral salpingo-oophorectomy (BSO) makes sense for you. Beyond that, genetic counseling and testing is worth pursuing if you haven’t already.

For STIC

STIC requires more careful consideration because it’s more likely to progress to invasive cancer. Management options include:

Complete surgical staging: This may involve removing both ovaries if still present, hysterectomy, omentectomy (removal of fatty tissue in the abdomen), and examination of the peritoneal cavity for signs of spread. 

However, there is currently no clear consensus recommending this approach universally. According to the NCCN’s 2025 guidelines, management options include observation alone (with or without CA-125 testing) when no invasive cancer is detected, or surgical staging if invasive cancer is confirmed. The guidelines acknowledge openly that it’s not yet clear whether surgical staging or adjuvant chemotherapy offers meaningful benefit for isolated STIC findings.

Research reflects this uncertainty: one large review found complete surgical staging was performed in only 28.6% of STIC cases, and those cases did not reveal invasive malignancies. An ongoing clinical trial (NCT04251052) is actively tracking STIC incidence and outcomes to help answer these open questions. Which means clearer guidance may be on the horizon, but isn’t here yet.

Surveillance: For isolated STIC in women who’ve already had both ovaries and tubes removed, close monitoring may be appropriate. This typically includes regular pelvic imaging and tumor marker assessment, though the exact protocol isn’t standardized.

Chemotherapy is rarely recommended unless there’s evidence of invasive disease. The data doesn’t support routine chemotherapy for STIC alone.

The decision depends on multiple factors: whether you still have your ovaries, your genetic risk status, the number of lesions found, and whether pelvic washings show abnormal cells.

Prevention Strategies: Opportunistic Salpingectomy

One of the most exciting developments in ovarian cancer prevention is the concept of opportunistic salpingectomy: removing the fallopian tubes during other pelvic surgeries.

If you’re having a hysterectomy for benign reasons and do not want children, removing your fallopian tubes at the same time could reduce your ovarian cancer risk by approximately 42 to 65%.

Research has also found significantly decreased ovarian cancer incidence among women who had opportunistic salpingectomy compared to those who didn’t. The procedure adds minimal time, cost, or risk to surgery you’re already having.

For High-Risk Women: Risk-Reducing Surgery

If you carry a BRCA1 or BRCA2 mutation, risk-reducing salpingo-oophorectomy (RRSO) — removing both fallopian tubes and ovaries — remains the gold standard for prevention.

RRSO is typically recommended:

• At age 35-40 for BRCA1 carriers
• At age 40-45 for BRCA2 carriers

This surgery reduces ovarian cancer risk and improves overall survival. But it also triggers immediate surgical menopause, which comes with its own challenges: hot flashes, bone density loss, cardiovascular risks, and sexual health changes.

Newer approaches are being studied, including:

• Removing just the fallopian tubes initially, then the ovaries later
• Radical fimbriectomy (removing the fimbriated end of the tube plus adjacent ovarian tissue)

These strategies aim to reduce cancer risk while preserving ovarian function longer, though they’re still considered investigational.

The Bottom Line: Knowledge Is Power

Fallopian tube lesions represent one of the most significant advances in understanding how high-grade serous ovarian cancer develops. While finding out you have a precancerous change can be unsettling, it also offers something women haven’t had before: a window for intervention before cancer develops.

If you’ve been diagnosed with a fallopian tube lesion:

• Get genetic counseling if you haven’t already
• Understand which type of lesion you have and what it means for your individual risk
• Work with a gynecologic oncologist who specializes in these conditions
• Consider your options carefully, balancing cancer risk against quality of life concerns
• Stay informed about emerging research and clinical trials

The science of prevention is advancing rapidly. What we learn from studying fallopian tube lesions today could save thousands of lives tomorrow.